Quercetin-Amino Acid Conjugates are Promising Anti-Cancer Agents in Drug Discovery Projects.

Quercetin is a plant flavonoid with great potential for the prevention and treatment of disease. Despite the curative application of quercetin is hampered by low bioavailability, its core serves as a scaffold for generating more potent compounds with amplified therapeutic window. This review aims to describe recent advances in the improvement of the pharmacokinetic profile of quercetin via the amino acid prodrug approach which offers wide structural diversity, physicochemical and biological properties improvement.

Internet of things technologies in medical sector: cyber security issues.

Objective: Introduction: One of the areas of the Internet of Things (further IoT) popularisation is medicine. Along with significant progress in this area, cyber security threats are on the rise. Thus, the issue of IoT technology's scientific understanding in medicine is of particular relevance.

Peripheral arteriovenous fistula as vascular access for long-term chemotherapy.

Introduction: To provide long-term vascular access in clinical oncology peripheral forearm veins (up to 95% of patients in Ukraine), central venous access and "complete implanted vascular systems" are used most often. Many oncology patients have contraindications to catheterization of superior vena cava. Besides, exploitation of central veins is associated with potential technical and infectious complications.

[Fraxiparin as a component of lymphotropic polychemotherapy of locally spread valvular cancer in patients with chronic venous insufficiency].

A total of 29 female patients with locally spread cancer of the vulva in chronic venous insufficiency underwent lymphotropic polychemotherapy. Of these, 16 subjects (55.2%) had varicosis, 13 (44.

[Treatment of dystrophy, dysplasia and initial stages of vulvar carcinoma in virus infections].

Overall sixty-seven patients with distrophy, dysplasia and valvular carcinoma presenting with human papilloma virus- and herpes simplex-2 virus infections underwent a complex treatment intended for background, precancerous affections of the vulva and for valvular carcinoma, involving the use of antiviral drug preparations laferon, zovirax, lovir (both on the systemic and local basis), and an immunomodulator (decaris). Efficacy of the above treatment option has been shown to be 98.5%.